H.C. Wainwright analyst Ed Arce raised the firm’s price target on Travere Therapeutics (TVTX) to $22 from $18 and keeps a Buy rating on the shares following the Q4 beat. The company’s preliminary results show 40% Filspari quarterly net sales growth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX: